Vasoactive Intestinal Peptide Receptor Gene Repressor Protein, Rat, Control Peptide (VIPRRP)
Catalog No : USB-V2115-18A
417.25€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Vasoactive Intestinal Peptide Receptor Gene Repressor Protein, Rat, Control Peptide (VIPRRP) | ||
|---|---|---|---|
| Catalog No | USB-V2115-18A | ||
| Supplier’s Catalog No | V2115-18A | ||
| Supplier | US Biologicals | ||
| Source antigen | Rat synthetic peptide | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | Purified | ||
| Form | Supplied as a lyophilized powder from PBS, 0.05% sodium azide. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Purified | ||
| Description | Rat Vasoactive intestinal peptide receptor-gene repressor protein (VIPRRP) Control/blocking peptide Vasoactive intestinal peptide (VIP) is a 28-aminoacid peptide (human, chr 6q26-q27). Expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a Mol.wt of 20kD. VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder. VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein). VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family. The VIP is 100% conserved in mouse, rat and human. VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. VIPRRP is a novel transcriptional repressor protein (656aa, rat) that regulates VIPR expression; it encodes a 72kD novel protein that interacts specifically with VIPR repressor element. Expression of VIPRRP led to transcriptional repression, thus indicating, positive and negative factors interact with VIPR promoter to regulate its expression. The VIPRRP is 78% identical to a previously characterized protein, differentiation-specific element binding protein, which is a member of a family of proteins including components of DNA replication factor C complex. Source: 17-aa peptide from Rat VIPRRP (1) Location: ~C-terminus Recommended Usage ELISA: Control peptide can be used to coat ELISA plates at 1ug/ml and detected with antibodies (0.5-1ug/ml for affinity pure). The rat VIPRRP11-P control peptide shows no significant homology with other species. Control peptide, because of its low mol. Wt (<3kD), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10ug control peptide per 1ug of affinity purified IgG or 1ul antiserum) to confirm antibody specificity . Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved